Repligen (RGEN) Could Be 10% Undervalued On Its Growth Narrative

Repligen (RGEN) is back on investor watch after fresh one day volatility, with the share price slipping 4.8% to close at US$175.42, even as longer term returns remain positive.

Recent trading has been choppy rather than trendless, with Repligen’s 1 day share price return down 4.75% even as the 90 day share price return is up 28.05% and the 1 year total shareholder return sits at 13.51%. This hints that momentum has cooled but not reversed.

Spot fresh moves in bioprocessing and life sciences by scanning our hand picked 20 high quality undiscovered gems alongside Repligen.

After a near 30% climb over 90 days and a sharp single day pullback, the question for Repligen now is whether meaningful upside still lies ahead or if most of the rerating is already in the rear view.

Most Popular Narrative: 10% Undervalued

On the widely followed narrative, Repligen is priced below an estimated fair value of $194.95, compared with the latest close at $175.42. This puts the focus squarely on whether its growth engines can justify that gap.

Strategic push into fast-growing modalities like cell therapy and ADCs, combined with continued innovation in filtration and PAT-enabled systems, is expected to enhance product mix toward higher-margin offerings and drive gross margin expansion over the next several years.

Continued product launches (new resins, Metenova single-use mixers, integrated PAT platforms) and recent acquisitions (e.g., 908 bioprocessing) are building additional recurring consumable pull-through and expanding the addressable market, directly supporting long-term revenue and operating margin growth.

See why 9 investors see Repligen as 10% undervalued.

Result: Fair Value of $194.95 (UNDERVALUED)

Still, the Repligen story could be knocked off course if biotech funding stays weak or if the BioLife Solutions deal proves harder to integrate.

Find out about the key risks to this Repligen narrative.

Another View: Repligen Looks Expensive On Sales

The fair value narrative paints Repligen as about 10% undervalued at $194.95, yet the current P/S ratio of 12.6x tells a tougher story. That multiple is almost triple the US Life Sciences sector at 4.5x and well above the estimated fair ratio of 6.5x, which signals real valuation risk if enthusiasm for the story cools.

To stress test that gap from a different angle, it helps to see what the numbers say in a full valuation breakdown. This includes how that P/S figure compares across peers and through time, before deciding how much of a premium feels comfortable for this kind of growth profile. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on Repligen’s valuation and business momentum can pull you in both directions, so it makes sense to inspect the underlying data now and decide where you land on that balance of risks and potential upside. To see the full picture from both angles, start with 2 key rewards and 1 important warning sign.

Looking for more Repligen sized investment ideas?

If Repligen has your attention, do not stop here. Broaden your watchlist with fresh ideas that match different risk levels and income goals.

• Target resilient balance sheets and steady fundamentals by scanning our list of solid balance sheet and fundamentals (25 results) so your shortlist is built on financial strength first.
• Hunt for quality at a potential discount by reviewing the 33 high quality undervalued stocks before prices move away from you.
• Stack potential income alongside capital growth by checking out the 8 dividend fortresses while yields and payout histories still look appealing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com